MEN’S HEALTH QUARTERLY
Longevity

Sermorelin Benefits: What Human Studies Show and What They Do Not

Clinic pages list a long set of sermorelin benefits. Here is each one sorted by the human evidence behind it.

Words by the editors ·

The benefits of sermorelin that are backed by human studies are narrow: it is used as a diagnostic test for growth hormone deficiency, and in children with that deficiency it increased growth in some trials.1 In adults, small studies show it or a close relative raises growth hormone, and sometimes IGF-1, but they show far less about muscle, fat, sleep or energy.2,3,6 Most of the benefits listed on clinic and supplement pages are claims, not findings. Below, each benefit is sorted by how much evidence stands behind it.

In brief

  • Sermorelin's best-supported uses are a diagnostic test for growth hormone deficiency and growth in some children with that deficiency.1
  • In 19 people aged 55 to 71, 16 weeks of a related GHRH analog raised growth hormone and IGF-I, and lean mass, well-being and libido in men only; sleep quality did not change.2
  • In 11 older men, six weeks of nightly GHRH raised nighttime growth hormone but did not change IGF-I or DEXA muscle and fat.3
  • No sermorelin label is listed in DailyMed, and compounded drugs are not FDA-approved.4,5

What is sermorelin supposed to do?

Sermorelin is a 29 amino acid analogue of human growth hormone-releasing hormone (GHRH), the signal the brain sends to the pituitary gland to release growth hormone. A review of the drug describes it as the shortest synthetic peptide with the full biological activity of GHRH, and says that intravenous and subcutaneous doses specifically stimulate growth hormone secretion.1 Every claimed benefit comes from that one action: more growth hormone, then more IGF-1, then changes in body composition, recovery and sleep. Each link in that chain has to be shown separately, and the studies below show how far each link has been tested. For the basics, see our explainer on what sermorelin is.

Which sermorelin benefits have the most evidence?

Two uses have the strongest support, and both come from children and diagnostic testing, not from healthy adults seeking a physique or energy change.

Neither of these tells an adult man what to expect. A child with a diagnosed deficiency, a weight-based dose and a growth chart is a different case from a healthy adult asking about energy.

What do studies in adults show?

Adult data are small, old and mixed. The table lists the three studies most often cited, with what each measured and what it did not show.

StudyWho and whatWhat changedWhat did not
Khorram, 1997219 people aged 55 to 71 (9 men, 10 women), single-blind placebo-controlled, 16 weeks of a modified GHRH analog, [Nle27]GHRH(1-29), at 10 micrograms per kilogram nightly. This is a close relative of sermorelin, not sermorelin itself.Growth hormone and IGF-I rose. Skin thickness rose in both sexes. In men only: lean body mass, insulin sensitivity, general well-being and libido.Blood pressure, body weight and bone density were unaffected, and sleep quality did not change. The only adverse effect was transient raised blood fats.
Vittone, 1997311 healthy men aged 64 to 76 with low baseline IGF-I, 6 weeks of 2 mg GHRH(1-29) injected nightly, no control group reported in the abstract.Nighttime growth hormone release rose. Two of six strength measures (upright row, shoulder press) and an abdominal crunch endurance test improved.IGF-I did not change, and neither did DEXA measures of muscle and fat, weight, glucose or lipids. The authors concluded single nightly doses were less effective than multiple daily doses.
Sigalos, 20176Retrospective chart review: 14 men (mean age 33.2) who took 100 mcg each of GHRP-6, GHRP-2 and sermorelin three times a day, picked from 105 who were prescribed it, all on testosterone therapy.Mean IGF-1 rose from 159.5 to 239.0 ng/mL over about 134 days.No control group, a three-drug combination so sermorelin's own part is unknown, and no body composition or symptom outcome reported.

Read together, the studies support one benefit: growth hormone and sometimes IGF-1 can be raised. A 2018 review of growth hormone secretagogues said the class might improve lean mass in wasting states and in obese individuals, decrease bone turnover, increase fat-free mass and improve sleep. The same review said that few long-term, rigorously controlled studies exist, and called for more work on long-term safety.7

Does sermorelin help with muscle, fat loss or energy?

Muscle: the evidence is mixed. Lean mass rose in the men of the 16-week analog trial, but DEXA muscle and fat did not change in the 6-week study of older men, and there are no controlled sermorelin trials in healthy adult men tracking body composition.2,3 A 2026 review of peptides sold for physique and performance goals describes the human evidence for putative performance and recomposition benefits as uncertain.8 Our piece on sermorelin before and after goes through those studies measure by measure.

Fat loss: we found no randomized trial of sermorelin for weight loss, which is covered in sermorelin for weight loss. The small signal in the table is lean mass and insulin sensitivity in older men, not fat loss.

Energy and libido: the only signal is the well-being and libido scores in the nine men of the analog trial, a self-reported outcome in a tiny group.2 It is a reason to run a larger trial, not a reason to expect the same result.

What about sleep?

Better sleep is among the most common claims. The 2018 review lists improved sleep among things growth hormone secretagogues might do, but across the class, not for sermorelin specifically.7 The one placebo-controlled adult trial that measured sleep with questionnaires found sleep quality unaffected in both men and women.2 Treat sleep benefit as unproven.

Is sermorelin FDA-approved for these benefits?

No sermorelin label is listed. A DailyMed search for sermorelin on October 29, 2026 returned no results.4 Adults who receive it today get a compounded product, and the FDA states that compounded drugs are not FDA-approved, meaning the agency does not verify their safety, effectiveness or quality before they are marketed.5 That is why the evidence above matters: there is no regulator-approved list of benefits for an adult to point to.

What are the downsides to weigh against the benefits?

In the pediatric review, the most commonly reported adverse events were transient facial flushing and pain at the injection site.1 The 2018 secretagogue review noted some concern for higher blood glucose through reduced insulin sensitivity, and said safety with long-term use, including cancer incidence and mortality, still needs evaluation.7 The 2026 review lists dysglycaemia, fluid retention, joint and muscle pain and injection-site reactions among adverse effects reported with peptides in this group.8 The details are in sermorelin side effects.

How to judge a page that lists sermorelin benefits

Limits of the evidence

The adult studies are from 1997 to 2017, the largest enrolled 19 people, none of the three in the table is a randomized sermorelin trial in healthy men, and two used a different GHRH molecule or a combination. IGF-1 is a marker, not a symptom. A higher number on a blood test does not by itself mean a man feels or functions better. Anyone considering a prescription should discuss it with a licensed clinician who can review their history, medications and lab results.

Talk to a clinician. This article explains the evidence; it cannot tell you what is right for you. A licensed clinician who knows your health history and medications can.
Important safety information. NAD+ and sermorelin are prescription injections. Compounded versions are not FDA-approved.5 Tell the prescribing clinician about every medication and supplement you take, and about any history of cancer, pituitary or thyroid conditions, or pregnancy. Only a licensed clinician who knows your health history should decide whether a prescription is appropriate for you.

Questions

What are the benefits of sermorelin?

The best-supported uses are a diagnostic test for growth hormone deficiency and increased growth in some children with that deficiency. In adults, small studies of sermorelin or related peptides show higher growth hormone, and sometimes IGF-1, but little proof of benefit for muscle, fat loss or sleep.

Does sermorelin build muscle?

Evidence is mixed. Lean body mass rose in the men of a 16-week trial of a related analog, but DEXA muscle and fat did not change in a 6-week study of older men, and no controlled sermorelin trial in healthy adult men has tracked body composition.

Does sermorelin help you sleep?

Unproven. A review lists improved sleep as something growth hormone secretagogues might do, but the one placebo-controlled adult trial that asked about sleep found sleep quality unchanged.

Is sermorelin FDA-approved?

No sermorelin label was listed in a DailyMed search on October 29, 2026. Adults receive compounded sermorelin, and the FDA says compounded drugs are not FDA-approved.

Also in this edition

Part of our guide: Sermorelin: The Complete Guide

Notes

  1. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. PubMed 18031173.
  2. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997. PubMed 9141536.
  3. Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997. PubMed 9005976.
  4. Sermorelin search. DailyMed, U.S. National Library of Medicine. Searched October 29, 2026.
  5. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
  6. Sigalos JT, et al. Growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels. Am J Mens Health. 2017. PubMed 28830317.
  7. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018. PubMed 28400207.
  8. Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol. 2026. PubMed 42395176.